VanEck Associates’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.42M | Sell |
16,606
-957
| -5% | -$355K | ﹤0.01% | 773 |
|
|
2026
Q1 | $5.14M | Sell |
17,563
-10,470
| -37% | -$3.44M | ﹤0.01% | 802 |
|
|
2025
Q4 | $9.83M | Buy |
28,033
+8,127
| +41% | +$2.75M | 0.01% | 567 |
|
|
2025
Q3 | $6.43M | Buy |
19,906
+1,874
| +10% | +$583K | 0.01% | 673 |
|
|
2025
Q2 | $7.01M | Sell |
18,032
-335
| -2% | -$135K | 0.01% | 598 |
|
|
2025
Q1 | $7.99M | Buy |
18,367
+3,483
| +23% | +$1.4M | 0.01% | 547 |
|
|
2024
Q4 | $5.49M | Buy |
14,884
+2,102
| +16% | +$880K | 0.01% | 652 |
|
|
2024
Q3 | $5.31M | Buy |
12,782
+507
| +4% | +$271K | 0.01% | 622 |
|
|
2024
Q2 | $6.65M | Buy |
12,275
+411
| +3% | +$217K | 0.01% | 507 |
|
|
2024
Q1 | $6.15M | Buy |
11,864
+575
| +5% | +$286K | 0.01% | 520 |
|
|
2023
Q4 | $5.32M | Buy |
11,289
+245
| +2% | +$113K | 0.01% | 524 |
|
|
2023
Q3 | $4.81M | Buy |
11,044
+172
| +2% | +$78K | 0.01% | 512 |
|
|
2023
Q2 | $4.83M | Buy |
10,872
+5,629
| +107% | +$2.6M | 0.01% | 522 |
|
|
2023
Q1 | $2.41M | Buy |
5,243
+359
| +7% | +$171K | 0.01% | 663 |
|
|
2022
Q4 | $2.5M | Sell |
4,884
-1,476
| -23% | -$749K | 0.01% | 630 |
|
|
2022
Q3 | $2.89M | Buy |
6,360
+25
| +0.4% | +$12K | 0.01% | 569 |
|
|
2022
Q2 | $3.06M | Buy |
6,335
+71
| +1% | +$35.1K | 0.01% | 570 |
|
|
2022
Q1 | $3.08M | Sell |
6,264
-1,131
| -15% | -$517K | 0.01% | 609 |
|
|
2021
Q4 | $3.43M | Sell |
7,395
-41
| -0.6% | -$17.2K | 0.01% | 593 |
|
|
2021
Q3 | $2.77M | Buy |
7,436
+642
| +9% | +$244K | 0.01% | 589 |
|
|
2021
Q2 | $2.59M | Buy |
6,794
+189
| +3% | +$72.2K | 0.01% | 600 |
|
|
2021
Q1 | $2.37M | Sell |
6,605
-709
| -10% | -$228K | 0.01% | 571 |
|
|
2020
Q4 | $2.35M | Buy |
7,314
+1,277
| +21% | +$392K | 0.01% | 516 |
|
|
2020
Q3 | $1.62M | Sell |
6,037
-6,440
| -52% | -$1.73M | 0.01% | 538 |
|
|
2020
Q2 | $3.28M | Sell |
12,477
-3,908
| -24% | -$1.04M | 0.01% | 397 |
|
|
2020
Q1 | $3.72M | Sell |
16,385
-2,038
| -11% | -$555K | 0.02% | 371 |
|
|
2019
Q4 | $5.56M | Buy |
18,423
+725
| +4% | +$200K | 0.02% | 349 |
|
|
2019
Q3 | $4.25M | Buy |
17,698
+557
| +3% | +$153K | 0.02% | 359 |
|
|
2019
Q2 | $4.84M | Buy |
17,141
+1,514
| +10% | +$414K | 0.02% | 347 |
|
|
2019
Q1 | $4.49M | Buy |
15,627
+12,635
| +422% | +$3.65M | 0.02% | 347 |
|
|
2018
Q4 | $786K | Buy |
2,992
+102
| +4% | +$28K | ﹤0.01% | 575 |
|
|
2018
Q3 | $792K | Sell |
2,890
-38
| -1% | -$9.87K | ﹤0.01% | 608 |
|
|
2018
Q2 | $697K | Buy |
+2,928
| New | +$678K | ﹤0.01% | 623 |
|
Other funds holding ELV
VanEck Associates's ELV Position: Q2 2026 in Review
VanEck Associates reduced its Elevance Health (ELV) stake by 5.4% in Q2 2026, selling an estimated $355K and leaving 16,606 shares worth $6.42M. The position accounts for ﹤0.01% of the portfolio, ranked #773.
VanEck Associates first reported a position in ELV in Q2 2018 and has held it in 33 quarters since. The position peaked at $9.83M in Q4 2025. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- VanEck Associates held 16,606 shares of Elevance Health worth $6.42M as of Q2 2026.
- VanEck Associates sold 957 Elevance Health shares in Q2 2026, an estimated $355K.
- Elevance Health made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #773 holding.
- VanEck Associates first reported a position in Elevance Health in Q2 2018 and has held it in 33 quarters since.
- VanEck Associates's Elevance Health position peaked at $9.83M in Q4 2025.
- 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.